Abstract
We modelled and characterised rux resistance in JAK2r B-ALL in vitro to enable development of therapeutic strategies to overcome or avert resistance in these high-risk patients.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Publication status | Published - 30 May 2018 |
| Externally published | Yes |
| Event | Adelaide Protein Group Student Awards 2018 - Adelaide, Australia Duration: 30 May 2018 → … |
Conference
| Conference | Adelaide Protein Group Student Awards 2018 |
|---|---|
| Abbreviated title | APG Student Awards 2018 |
| Country/Territory | Australia |
| City | Adelaide |
| Period | 30/05/18 → … |
Keywords
- Ruxolitinib
- Mutation
- Pro-B Cells
- B-ALL JAK2-fusion
Fingerprint
Dive into the research topics of 'Identification of ruxolitinib resistant mutations in Pro-B cells driven by a high-risk B-ALL JAK2 Fusion'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Precision medicine approaches for JAK2-rearranged ALL: The efficacy of targeted therapies and molecular mechanisms of drug resistance
Toomes, C. (Associate Investigator), White, D. L. (Chief Investigator (Project Lead)), McClure, B. (Associate Investigator) & Bruning, J. B. (Associate Investigator)
12/03/18 → 31/12/22
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver